Dr. Timothy L. Jackson, MD
Internal Medicine (Internal Medicine Physician)
Who else practices at this address →
Beaver County includes primary care (3% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Hahnemann University College of Medicine (1989)
- Years since graduation
- 37
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 311
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1989Medical school: Hahnemann University College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
PA license MD044713L · OH license 35-063422
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Magee Womens Hospital of UPMC Health System Pittsburgh, PA
- Heritage Valley Beaver Beaver, PA
- Heritage Valley Sewickley Sewickley, PA
Medical groups
- Heritage Valley Multispecialty Group Inc (227 clinicians)
- Mrs Physical Therapy (182 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 311
- Services billed
- 3,574
- Patients’ average age
- 78
| Service | Times | Patients |
|---|---|---|
| Injection, denosumab, 1 mg | 1,080 | 11 |
| Residence visit for established patient with moderate level of medical decision making, per day, if using time, at least 40 minutes | 372 | 91 |
| Established patient office or other outpatient visit, 30-39 minutes | 333 | 197 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 164 | 164 |
| Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes | 93 | 54 |
| Residence visit for established patient with high level of medical decision making, per day, if using time, at least 60 minutes | 51 | 33 |
| Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage | 34 | 34 |
| Established patient office or other outpatient visit, 20-29 minutes | 33 | 30 |
| Injection of drug or substance under skin or into muscle | 32 | 18 |
| Administration of influenza virus vaccine | 25 | 25 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 5 payments worth $109 in total to this clinician.
| Recor Medical Inc | $28.13 |
|---|---|
| Abbott Laboratories | $21.64 |
| Novo Nordisk Inc | $20.93 |
| AbbVie Inc. | $20.07 |
| Amgen Inc. | $18.71 |
| Food and Beverage | $109 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 3 companies. The companies reported $503,146 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with establish…
Boehringer Ingelheim Pharmaceuticals, Inc. - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in p…
Boehringer Ingelheim Pharmaceuticals, Inc. - A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD
Boehringer Ingelheim Pharmaceuticals, Inc. - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in p…
Boehringer Ingelheim Pharma GmbH & Co.kg - A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with establish…
Boehringer Ingelheim International GmbH - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in p…
Boehringer Ingelheim International GmbH - A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD
Boehringer Ingelheim International GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.